Discovery of a genetically modified factor for breast cancer treatment.

Australian researchers have discovered a genetic mutation that could open up new avenues for treating breast cancer patients.

This factor is the molecule ELF5, which allows doctors to modify cancer cells, making treatments such as anti-oestrogen therapies more effective.

Research by experts at the Garvan Institute of Medical Research in Sydney shows that the molecule ELF5 can cause genes in cells to be activated or deactivated.

Illustrative image. (Source: bacsivn.com)

By manipulating these molecules, the sensitivity of breast cancer cells to anti-hormonal therapy is significantly increased.

Professor Chris Ormandy stated: "ELF5 molecules determine how cancer cells respond to anti-female hormone therapy."

This discovery has for the first time demonstrated an interaction between the molecule ELF5 and breast cancer. Previously, this molecule had been found in all breast cancer cells by Professor Ormandy's research group since 1999.

By 2008, this same group had demonstrated that ELF5 stimulates milk production in women.

This discovery is believed to open up prospects for developing targeted drugs to kill cancer cells. Breast cancer patients may also be able to avoid the risk of having to use other toxic treatments such as chemotherapy.

Breast cancer is the most common type of cancer and the second leading cause of death among women.

In 2008, Australia had 13,600 breast cancer patients, and after 5 years of treatment, the survival rate was 89%.

According to (VNA) - VT